Theriva Biologics (NYSEAMERICAN:TOVX) Upgraded to Buy at Maxim Group

Theriva Biologics (NYSEAMERICAN:TOVX) was upgraded by investment analysts at Maxim Group from a “hold” rating to a “buy” rating in a research report issued to clients and investors on Tuesday,Benzinga reports. The firm presently has a $1.00 target price on the stock. Maxim Group’s price objective would indicate a potential upside of 410.73% from the stock’s current price.

Theriva Biologics Price Performance

Shares of TOVX traded up $0.01 during trading hours on Tuesday, reaching $0.20. The company had a trading volume of 2,013,266 shares, compared to its average volume of 12,327,300. The company has a current ratio of 1.74, a quick ratio of 1.74 and a debt-to-equity ratio of 0.11. Theriva Biologics has a 12-month low of $0.16 and a 12-month high of $1.50. The firm has a 50 day simple moving average of $0.19 and a 200-day simple moving average of $0.26. The company has a market capitalization of $6.61 million, a price-to-earnings ratio of -0.01 and a beta of 0.53.

Theriva Biologics (NYSEAMERICAN:TOVX) last posted its earnings results on Thursday, March 12th. The company reported $1.30 EPS for the quarter.

Institutional Investors Weigh In On Theriva Biologics

A hedge fund recently raised its stake in Theriva Biologics stock. Geode Capital Management LLC raised its holdings in Theriva Biologics, Inc. (NYSEAMERICAN:TOVX) by 651.8% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 212,087 shares of the company’s stock after purchasing an additional 183,878 shares during the period. Geode Capital Management LLC owned about 0.63% of Theriva Biologics worth $45,000 as of its most recent SEC filing. Institutional investors own 6.17% of the company’s stock.

About Theriva Biologics

Theriva Biologics, Inc, a clinical-stage company, develops therapeutics to treat cancer and related diseases in areas of high unmet need in the United States. The company’s lead product candidate is VCN-01, a clinical stage oncolytic human adenovirus that is in a Phase 2 clinical study for the treatment of pancreatic cancer; a Phase 1 clinical study for the treatment of retinalblastoma; a Phase 1 clinical study for the treatment of head and neck squamous cell carcinoma; and a Phase 1 clinical study for the treatment of solid tumors.